AstraZeneca Stock - Weekly review and big-pharma sector context
19.06.2026 - 21:32:45 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:28 CET. Details in the imprint.
AstraZeneca (US6549022043) remains one of the world’s largest pharmaceutical groups by market value. The stock has stepped back from recent highs, which puts this week’s performance and the company’s position within the big-pharma sector into sharper focus.
All news and key data on AstraZeneca stock
Stay on top of AstraZeneca’s latest share price moves, corporate news and sector comparisons with the dedicated topic page and the company’s own investor-relations updates.
How AstraZeneca shares fared this week
On the US market, AstraZeneca’s American depositary shares last closed around $174.90, implying a roughly 1.7% decline in the latest session according to recent trading data for ticker AZN on Nasdaq. That move came against a positive broader US equity backdrop.
In London, where AstraZeneca is a heavyweight in the FTSE 100, the stock recently changed hands near 13,234 pence. This level leaves the shares about 15.9% below their 52-week high of 15,732 pence reached on 02/18/2026, as market data from the Financial Times show.
Weekly review and sector comparison
With a market capitalization of roughly $269 billion based on the latest Nasdaq close, AstraZeneca ranks among the top global pharmaceutical names by value. The group therefore often trades as part of broader health care allocations in global and European benchmarks.
Against this backdrop, the roughly 1.7% drop in the ADR price this week stands out mainly because the Standard & Poor’s 500 index gained about 1.1% over the same session, while the tech-heavy Nasdaq Composite climbed nearly 1.9%. The move therefore reflects some stock-specific consolidation rather than a sector-wide sell-off.
What the company sells
AstraZeneca generates most of its revenue from prescription medicines in areas such as oncology, cardiovascular, renal and metabolism, and respiratory diseases. Key products include cancer therapies like Tagrisso and Imfinzi, as well as diabetes treatment Farxiga, which together underpin a diversified blockbuster portfolio.
Where the stock trades today
The shares of AstraZeneca (US6549022043) trade in the US as ADRs on Nasdaq at about $174.90 and in London around 13,234 pence as of 06/18/2026, 16:00 ET and 06/19/2026, 11:00 BST respectively.
Key facts on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: US6549022043
- WKN: 886455
- Ticker: AZN
- Venue: Nasdaq (ADR) / London Stock Exchange
- Price (as of 06/18/2026, 16:00 ET): 174.90 USD (ADR)
- Market cap: 269,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: FTSE 100, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
